TY - JOUR
T1 - Is ADHD a risk for posttraumatic stress disorder (PTSD)? Results from a large longitudinal study of referred children with and without ADHD
AU - Biederman, Joseph
AU - Petty, Carter
AU - Spencer, Thomas J.
AU - Woodworth, K. Yvonne
AU - Bhide, Pradeep
AU - Zhu, Jinmin
AU - Faraone, Stephen V.
N1 - Funding Information:
Dr Thomas Spencer has received research support from the following sources: Shire Laboratories Inc, Cephalon, Eli Lilly & Company, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, NIMH and the Department of Defense. Dr Spencer has been a speaker or on a speaker ’s bureau for the following pharmaceutical companies: Shire Laboratories, Inc, McNeil Pharmaceutical, and Novartis Pharmaceuticals. Dr Spencer has been an advisor or on an advisory board for the following pharmaceutical companies: Alcobra, Shire Laboratories Inc, Cephalon, Eli Lilly & Company, Janssen, McNeil Pharmaceutical, and Novartis Pharmaceuticals. Dr Spencer receives research support from Royalties and Licensing fees on copyrighted ADHD scales through MGH Corporate Sponsored Research and Licensing. Dr Spencer has a US Patent Application pending (Provisional Number #61/233,686),through MGH corporate licensing, on a method to prevent stimulant abuse.
Funding Information:
This manuscript was supported in part by grants to J. Biederman from the National Institute of Health (R01 HD36317, R01 MH50657) and the Pediatric Psychopharmacology Research Council Fund.
Funding Information:
In the past year, Dr Faraone received consulting income and/or research support from Shire, Otsuka and Alcobra and research support from the National Institutes of Health (NIH). He is also on the Clinical Advisory Board for Akili Interactive Labs. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr Faraone receives royalties from books published by Guilford
Funding Information:
Dr Joseph Biederman is currently receiving research support from the following sources: Elminda, Janssen, McNeil, and Shire. In 2012, Dr. Joseph Biederman received an honorarium from the MGH Psychiatry Academy and The Children’s Hospital of Southwest Florida/Lee Memorial Health System for tuition-funded CME courses. In 2011, Dr Biederman gave a single unpaid talk for Juste Pharmaceutical Spain, received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course, and received an honorarium for presenting at an international scientific conference on ADHD. He also received an honorarium from Cambridge University Press for a chapter publication. Dr Biederman received departmental royalties from a copyrighted rating scale used for ADHD diagnoses, paid by Eli Lilly, Shire and Astra-Zeneca; these royalties are paid to the Department of Psychiatry at MGH. In 2010, Dr Biederman received a speaker’ s fee from a single talk given at Fundaci ó n Dr. Manuel Camelo A.C. in Monterrey Mexico. Dr Biederman provided single consultations for Shionogi Pharma Inc. and Cipher Pharmaceuticals Inc.; the honoraria for these consultations were paid to the Department of Psychiatry at the MGH. Dr Biederman received honoraria from the MGH Psychiatry Academy for a tuition-funded CME course. In previous years, Dr Biederman received research support, consultation fees, or speaker ’s fees for/from the following additional sources: Abbott, Alza, AstraZeneca, Boston University, Bristol Myers Squibb, Celltech, Cephalon, Eli Lilly and Co., Esai, Fundacion Areces (Spain), Forest, Glaxo, Gliatech, Hastings Center, Janssen, McNeil, Medice Pharmaceuticals (Germany), Merck, MMC Pediatric, NARSAD, NIDA, New River, NICHD, NIMH, Novartis, Noven, Neurosearch, Organon, Otsuka, Pfizer, Pharmacia, Phase V Communications, Physicians Academy, The Prechter Foundation, Quantia Communications, Reed Exhibitions, Shire, the Spanish Child Psychiatry Association, The Stanley Foundation, UCB Pharma Inc., Veritas, and Wyeth.
PY - 2014/1
Y1 - 2014/1
N2 - Objectives. Preclinical studies link prenatal nicotine exposure with the development of both ADHD-like phenotype in rodents and blockade of extinction learning in a fear conditioning paradigm, a preclinical model of posttraumatic stress disorder (PTSD). While these findings suggest that either ADHD, prenatal nicotine exposure, or both could be a risk factor for PTSD, such associations have not been investigated in humans. Methods. Subjects were ascertained from family-genetic, longitudinal studies of paediatrically and psychiatrically referred children with and without ADHD of both sexes and their siblings followed for 10 years from childhood into adulthood (n = 403 probands; n = 464 siblings; mean age at follow-up of probands and siblings = 22.0 years). All subjects were comprehensively evaluated with structured diagnostic interviews that included questions regarding prenatal use of cigarettes. Results. A total of 12% (104/867) of the sample had been exposed to maternal smoking during pregnancy. There was no interaction effect between maternal smoking during pregnancy and ADHD (z = 0.01, P = 0.99). Maternal smoking during pregnancy and ADHD were independent, significant risk factors for PTSD at the 10-year follow-up (odds ratio = 3.58 [1.35,9.48], z = 2.57, P = 0.01 and odds ratio = 2.23 [1.06,4.69], z = 2.11, P = 0.04, respectively). Conclusions. These results suggest that both maternal smoking during pregnancy and ADHD are significant predictors of PTSD in humans.
AB - Objectives. Preclinical studies link prenatal nicotine exposure with the development of both ADHD-like phenotype in rodents and blockade of extinction learning in a fear conditioning paradigm, a preclinical model of posttraumatic stress disorder (PTSD). While these findings suggest that either ADHD, prenatal nicotine exposure, or both could be a risk factor for PTSD, such associations have not been investigated in humans. Methods. Subjects were ascertained from family-genetic, longitudinal studies of paediatrically and psychiatrically referred children with and without ADHD of both sexes and their siblings followed for 10 years from childhood into adulthood (n = 403 probands; n = 464 siblings; mean age at follow-up of probands and siblings = 22.0 years). All subjects were comprehensively evaluated with structured diagnostic interviews that included questions regarding prenatal use of cigarettes. Results. A total of 12% (104/867) of the sample had been exposed to maternal smoking during pregnancy. There was no interaction effect between maternal smoking during pregnancy and ADHD (z = 0.01, P = 0.99). Maternal smoking during pregnancy and ADHD were independent, significant risk factors for PTSD at the 10-year follow-up (odds ratio = 3.58 [1.35,9.48], z = 2.57, P = 0.01 and odds ratio = 2.23 [1.06,4.69], z = 2.11, P = 0.04, respectively). Conclusions. These results suggest that both maternal smoking during pregnancy and ADHD are significant predictors of PTSD in humans.
KW - ADHD
KW - Anxiety
KW - Nicotine
KW - PTSD
KW - Smoking
UR - https://www.scopus.com/pages/publications/84892377999
U2 - 10.3109/15622975.2012.756585
DO - 10.3109/15622975.2012.756585
M3 - Article
C2 - 23607442
AN - SCOPUS:84892377999
SN - 1562-2975
VL - 15
SP - 49
EP - 55
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 1
ER -